Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes.
Journal Information
Full Title: Cancer Manag Res
Abbreviation: Cancer Manag Res
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Disclosure NH reports consultancy or an advisory role for Stemline Therapeutics; honoraria from Incyte and Stemline Therapeutics; and research funding from Pfizer and Novartis. MJM reports consultancy for Novartis, Bristol Myers Squibb, Takeda, Pfizer, Sun Pharma/SPARC, and Abbvie; honoraria from Novartis, Bristol Myers Squibb, Takeda, and Pfizer; and research funding from Novartis, Bristol Myers Squibb, Takeda, and Sun Pharma/SPARC. The authors report no other conflicts of interest in this work."
"This manuscript was sponsored by Novartis Pharmaceuticals Corporation. Financial support for medical editorial assistance was also provided by Novartis. The sponsor was not involved in the writing of this review."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025